High CV risk in young people is a 'delayed' crisis

Published Date: 08 Mar 2023

Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.

Read Full News

Latest News

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

RLS-1496 Cream Reduces Actinic Keratosis Lesions Mary Spellman, MD

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Latest News

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

News All Time

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Recommended News For You

Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Researchers find distinct cell receptors with the potential for new treatments.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

How 7,000 steps a day could help reduce your risk of cancer

Recommended Articles For You

Clinical Pathways in Hematology in Clinical Decision-Making 

Bone Marrow Niche Regeneration Through Microenvironment Engineering 

Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology 

Long-Term Wellness After Childhood Cancer Therapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

2.

Research discovery halts childhood brain tumor before it forms

3.

CAR-T Warning for Secondary Malignancies: Warranted or Not?

4.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

5.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

1.

Geriatric Medicine Through Age-Associated Changes in Hematopoietic Reserve

2.

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures

3.

Clinical Analysis of Prostate Cancer

4.

Clinical Methods in Hematology and Quality Improvement

5.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

4.

Understanding the Role of Multidisciplinary Cancer Care

5.

A New Era in Managing Cancer-Associated Thrombosis

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot